Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.67%. A quarter ago, it was expected that this company would post a loss of $0.82 per share when it actually produced a loss of $0.34, delivering a surprise of +58.54%.Over the last four quarters, the compa ...